Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yota Sato

Showing results (41-50 of 44) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 44 results.
Oncotarget|April 13, 2018
Serum levels of soluble CD163 and CXCL5 may be predictive markers for immune-related adverse events in patients with advanced melanoma treated with nivolumab: a pilot studyTaku Fujimura, Yota Sato, Kayo Tanita, et al.
Frontiers in Medicine|May 14, 2019
Association of Baseline Serum Levels of CXCL5 With the Efficacy of Nivolumab in Advanced MelanomaTaku Fujimura, Yota Sato, Kayo Tanita, et al.
Frontiers in Oncology|December 5, 2018
Serum Level of Soluble CD163 May Be a Predictive Marker of the Effectiveness of Nivolumab in Patients With Advanced Cutaneous MelanomaTaku Fujimura, Yota Sato, Kayo Tanita, et al.
Allergology International : Official Journal of the Japanese Society of Allergology|October 19, 2024
Skin health survey on atopic dermatitis among Japanese children: The Tohoku Medical Megabank Project Birth and Three-Generation Cohort StudyChikana Kawaguchi, Maki Ozawa, Takanori Hidaka, et al.
Pageof 5

Showing results (41-50 of 44) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 44 results.
Oncotarget|April 13, 2018
Serum levels of soluble CD163 and CXCL5 may be predictive markers for immune-related adverse events in patients with advanced melanoma treated with nivolumab: a pilot studyTaku Fujimura, Yota Sato, Kayo Tanita, et al.
Frontiers in Medicine|May 14, 2019
Association of Baseline Serum Levels of CXCL5 With the Efficacy of Nivolumab in Advanced MelanomaTaku Fujimura, Yota Sato, Kayo Tanita, et al.
Frontiers in Oncology|December 5, 2018
Serum Level of Soluble CD163 May Be a Predictive Marker of the Effectiveness of Nivolumab in Patients With Advanced Cutaneous MelanomaTaku Fujimura, Yota Sato, Kayo Tanita, et al.
Allergology International : Official Journal of the Japanese Society of Allergology|October 19, 2024
Skin health survey on atopic dermatitis among Japanese children: The Tohoku Medical Megabank Project Birth and Three-Generation Cohort StudyChikana Kawaguchi, Maki Ozawa, Takanori Hidaka, et al.
Pageof 5